Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 17/20 | 0.86 |
| ▸ | HRH1 | P35367 | 13/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.86 |
| ▸ | ADRA1A | P35348 | 7/20 | 0.86 |
| ▸ | ADRA1B | P35368 | 7/20 | 0.86 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2852639 | 0.93 | HRH3 (1.00) | HRH3HRH1KCNH2ADRA1AADRA1B | |
| SCHEMBL2849054 | 0.91 | HRH3 (0.85) | HRH3HRH1KCNH2ADRA1AADRA1B | |
| SCHEMBL2878473 | 0.89 | HRH1 (0.69) | HRH3HRH1KCNH2ADRA1AADRA1B | |
| SCHEMBL2846839 | 0.87 | HRH3 (0.83) | HRH3HRH1KCNH2ADRA1AADRA1B | |
| SCHEMBL2852768 | 0.85 | HRH3 (1.00) | HRH3HRH1KCNH2ADRA1AADRA1B | |
| SCHEMBL2854545 | 0.84 | HRH3 (1.00) | HRH3HRH1KCNH2ADRA1AADRA1B | |
| SCHEMBL2852566 | 0.81 | HRH3 (0.72) | HRH3HRH1KCNH2ADRA1AADRA1B | |
| SCHEMBL2851067 | 0.80 | HRH3 (1.00) | HRH3HRH1KCNH2ADRA1AADRA1B | |
| SCHEMBL2854990 | 0.80 | HRH3 (0.81) | HRH3HRH1KCNH2ADRA1AADRA1B | |
| SCHEMBL2850767 | 0.78 | HRH1 (0.51) | HRH3HRH1KCNH2ADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027108-B1 | HISTAMINE RECEPTOR ANTAGONISTS COMPRISING AN AZEPIN CORE | GLAXO GROUP LTD (GB) | 2010-01-13 | — | — | EP | disclosed |
| US-20090181950-A1 | Histamine Receptor Antagonists Comprising an Azepin Core | GLAXO GROUP LIMITED (GB) | 2009-07-16 | — | — | US | disclosed |
| EP-2027108-A1 | HISTAMINE RECEPTOR ANTAGONISTS COMPRISING AN AZEPIN CORE | Glaxo Group Limited (GB) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007135081-A1 | HISTAMINE RECEPTOR ANTAGONISTS COMPRISING AN AZEPIN CORE | GLAXO GROUP LIMITED (GB) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181950-A1 | Histamine Receptor Antagonists Comprising an Azepin Core | HRH2, HRH1, HRH4 | HRH3 4/4885HRH1 2/4885KCNH2 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.